|
Jun 11
|
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
|
|
May 16
|
These 2 No-Brainer Growth Stocks Are Breaking New Ground
|
|
May 13
|
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
|
|
May 13
|
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
|
|
May 13
|
Pipeline Moves: Phase III completion for Corcept’s relaorilant
|
|
May 13
|
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
|
|
May 10
|
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
|
|
May 10
|
Q1 2024 Intellia Therapeutics Inc Earnings Call
|
|
May 9
|
Regeneron’s gene therapy triumphs twice, restoring hearing in children
|
|
May 8
|
Regeneron gene therapy improves hearing in two children
|
|
May 8
|
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
|
|
May 4
|
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
|
|
May 4
|
23 Most Profitable Stocks of the Last 12 Months
|
|
May 3
|
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Regeneron Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
|
|
May 3
|
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
|
|
May 3
|
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
|
|
May 3
|
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
|
|
May 2
|
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
|
|
May 2
|
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
|